Recombinant live Salmonella spp. for human vaccination against heterologous pathogens

被引：30
作者：
Bumann, D
Hueck, C
Aebischer, T
Meyer, TF
机构：
[1] Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany
[2] Creatogen Gmbh, D-86156 Augsburg, Germany
来源：
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2000年 / 27卷 / 04期
关键词：
attenuated live carrier; clinical trial; Salmonella vaccine;
D O I：
10.1016/S0928-8244(99)00214-X
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Live attenuated Salmonella spp. are promising candidates as oral vaccine delivery systems for heterologous antigens. Clinical trials have demonstrated that this approach is feasible for human vaccinations but further optimisation is necessary to obtain a better efficacy. Here, we discuss how existing clinical and pre-clinical data can be used to guide such optimisation efforts. (C) 2000 Federation of European Microbiological Societies. Published by Elsevier Science B.V, All rights reserved.
引用
收藏
页码：357 / 364
页数：8
相关论文
共 66 条
  • [1] Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection
    Altare, F
    Lammas, D
    Revy, P
    Jouanguy, E
    Döffinger, R
    Lamhamedi, S
    Drysdale, P
    Scheel-Toellner, D
    Girdlestone, J
    Darbyshire, P
    Wadhwa, M
    Dockrell, H
    Salmon, M
    Fischer, A
    Durandy, A
    Casanova, JL
    Kumararatne, DS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) : 2035 - 2040
  • [2] Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency
    Altare, F
    Durandy, A
    Lammas, D
    Emile, JF
    Lamhamedi, S
    Le Deist, F
    Drysdale, P
    Jouanguy, E
    Döffinger, R
    Bernaudin, F
    Jeppsson, O
    Gollob, JA
    Meinl, E
    Segal, AW
    Fischer, A
    Kumararatne, D
    Casanova, JL
    [J]. SCIENCE, 1998, 280 (5368) : 1432 - 1435
  • [3] The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice
    Benyacoub, J
    Hopkins, S
    Potts, A
    Kelly, S
    Kraehenbuhl, JP
    Curtiss, R
    De Grandi, P
    Nardelli-Haefliger, D
    [J]. INFECTION AND IMMUNITY, 1999, 67 (07) : 3674 - 3679
  • [4] PREVENTION OF SHIGELLOSIS BY A SALMONELLA-TYPHI-SHIGELLA SONNEI BIVALENT VACCINE
    BLACK, RE
    LEVINE, MM
    CLEMENTS, ML
    LOSONSKY, G
    HERRINGTON, D
    BERMAN, S
    FORMAL, SB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (06) : 1260 - 1265
  • [5] EFFICACY OF ONE OR 2 DOSES OF TY21A SALMONELLA-TYPHI VACCINE IN ENTERIC-COATED CAPSULES IN A CONTROLLED FIELD TRIAL
    BLACK, RE
    LEVINE, MM
    FERRECCIO, C
    CLEMENTS, ML
    LANATA, C
    ROONEY, J
    GERMANIER, R
    [J]. VACCINE, 1990, 8 (01) : 81 - 84
  • [6] CHATFIELD SN, 1997, NEW GENERATION VACCI, P331
  • [7] Corthésy-Theulaz IE, 1998, INFECT IMMUN, V66, P581
  • [8] Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin
    Covone, MG
    Brocchi, M
    Palla, E
    da Silveira, WD
    Rappuoli, R
    Galeotti, CL
    [J]. INFECTION AND IMMUNITY, 1998, 66 (01) : 224 - 231
  • [9] CURTISS R, 1994, DEV BIOL STAND, V82, P23
  • [10] SALMONELLA-TYPHIMURIUM DELETION MUTANTS LACKING ADENYLATE-CYCLASE AND CYCLIC-AMP RECEPTOR PROTEIN ARE AVIRULENT AND IMMUNOGENIC
    CURTISS, R
    KELLY, SM
    [J]. INFECTION AND IMMUNITY, 1987, 55 (12) : 3035 - 3043
1234567